A particularly aggressive, metastasizing form of cancer, HER2-positive breast cancer, may be treated with nanoscopic particles ''imprinted'' with specific binding sites for the receptor molecule HER2. The selective binding of the nanoparticles to HER2 significantly inhibits multiplication of the tumor cells.